How to reduce a risk of venous thromboembolism while taking combined oral contraceptives

The review presents data on the evolution of combined oral contraceptives (COCs), related most frequent and dangerous side effects including venous thromboembolism (VTE). The issue of VTE upon administration of COCs is highlighted, and the risks of such complication in patients receiving hormonal contraception are determined. The issues of the basic demands of women choosing COCs are considered as well as current opportunities to meet such requests by using novel drug groups with a high profile of efficacy and safety. Particular cases of optimal COCs choice for patients with specific comorbidities such as obesity, hirsutism, seborrhea, alopecia, acne, polycystic ovary syndrome (PCOS), fibrocystic mastopathy, endometriosis as well as in case of gynecological surgical interventions are analyzed. The options of contraceptive therapy are proposed by taking into account individual female wishes (lack of weight gain, decreased libido, etc.).

1. Liao P.V., Dollin J. Half a century of the oral contraceptive pill: historical review and view to the future. Can Fam Physician. 2012;58(12):e757–60.

2. Regidor P.A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9(77):34628–38. https://doi.org/10.18632/oncotarget.26015.

3. Bateson D., Butcher B.E., Donovan C. et al. Risk of venous thromboembolism in women taking the СОСs: A systematic review and meta-analysis. Aust Fam Physician. 2016;45(1):59–64.

4. De Leo V., Musacchio M.C., Cappelli V. et al. Hormonal contraceptives: pharmacology tailored to women's health. Hum Reprod Update. 2016;22(5):634–46. https://doi.org/10.1093/humupd/dmw016.

5. Dikke G.B. Just "a pill". Sixty years of discoveries and achievements which have changed the world. Part I. Hormonal contraception: from idea to excellence. [Prosto «tabletka». Shest`desyat let otkry`tij i dostizhenij, kotory`e izmenili mir. Chast` I. Gormonal`naya kontracepciya: ot idei k sovershenstvu]. Farmateka. 2019;27(6):38–45. (In Russ.). https://doi.org/10.18565/pharmateca.2020.6.10-17.

6. Fait T., Buryak D., Cirstoiu M.-M. et al. Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe. Drugs Context. 2018;7:212510. https://doi.org/10.7573/dic.212510.

7. van Vlijmen E.F., Wiewel-Verschueren S., Monster T.B., Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2016;14(7):1393–403. https://doi.org/10.1111/jth.13349.

8. Morimont L., Haguet H., Dogné J.M. et al. Combined oral contraceptives and venous thromboembolism: Review and perspective to mitigate the risk. Front Endocrinol (Lausanne). 2021;12:769187. https://doi.org/10.3389/fendo.2021.769187.

9. Mikhailova O.I., Mirzabekova D.D., Tyutyunnik V.L., Kan N.E. Choice of contraceptive method in the postpartum period. [Vybor metoda kontracepcii v poslerodovom periode]. Zarozhdenie zhizni. 2022;(1):40–4. (In Russ.). https://doi.org/10.46393/27826384_2022_1_40.

10. Guang-Sheng F., Mei-Lu B., Li-Nan C. et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig. 2010;30(6):387–96. https://doi.org/10.1007/BF03256908.

11. Caprio M., Antelmi A., Chetrite G. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152(1):113–25. https://doi.org/10.1210/en.2010-0674.

12. Wallwiener C.W., Wallwiener L.-M., Seeger H.et al. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med. 2010;7(6):2139–48. https://doi.org/10.1111/j.1743-6109.2010.01742.x.

13. Higgins J.A., Hoffman S., Graham S.A., Sanders S.A. Relationships between condoms, hormonal methods, and sexual pleasure and satisfaction: an exploratory analysis from the Women's Well-Being and Sexuality Study. Sex Health. 2008;5(4):321–3. https://doi.org/10.1071/sh08021.

14. Zdravomyslov V.I., Anisimova Z.E., Libikh S.S. Functional female sexual pathology. [Funkcional'naya zhenskaya seksopatologiya]. Perm': TOO firma «Reprint», 1994. 272 p. (In Russ.).

15. Sanders S.A., Graham C.A, Bass J.L., Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64(1):51–8. https://doi.org/10.1016/s0010-7824(01)00218-9.

16. Shamseddin M., De Martino F., Constantin C. et al. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Mol Med. 2021;13(7):e14314. https://doi.org/10.15252/emmm.202114314.

17. Musina E.V., Kogan I.Iu., Tarasova M.A. The therapeutic effect of desogestrel in women with mastalgia and mastopathy. [Lechebnoe dejstvie dezogestrela pri mastalgii u zhenshchin s fibrozno-kistoznoj bolezn'yu molochnyh zhelez]. Problemy reprodukcii. 2013;(5):42–6. (In Russ.).

18. Zhukovskaya I.G., Khuzina L.F. Some aspects of adherence to combined hormonal contraception in young women. [Nekotorye aspekty priverzhennosti k kombinirovannoj gormonal'noj kontracepcii u molodyh zhenshchin]. Medicinskij sovet. 2022;16(16):93–8. (In Russ.). https://doi.org/10.21518/2079-701X-2022-16-16-93-98.

19. Ebede T.L., Arch E.L., Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol. 2009;2(12):16–22.

20. Mueck A.O., Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011;76(6):531–9. https://doi.org/10.1016/j.steroids.2011.02.002.

21. Nappi R.E., Albani F., Tonani S. et al. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct Neurol. 2009;24(2):71–5.

22. Ndefo U.A., Eaton A., Green M.R. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013;38(6):336–55.

23. Amiri M., Kabir A., Nahidi F. et al. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2018;23(1):64–77. https://doi.org/10.1080/13625187.2018.1435779.

24. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A. et al. Human adipocytes secrete mineralcorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100(24):14211–6. https://doi.org/10.1073/pnas.2336140100.

25. Bird S.T., Hartzema A.G., Brophy J.M et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–20. https://doi.org/10.1503/cmaj.120677.

26. Dinger J.C., Heinemann L.A.J., Kühl-Habich D. The safety of a drosperinone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344–54. https://doi.org/10.1016/j.contraception.2006.12.019.

27. Bateson D., Butcher B.E., Donovan C. et al. Risk of venous thromboembolism in women taking the СОСs: A systematic review and meta-analysis. Aust Fam Physician. 2016;45(1):59–64.